SG11201901528RA - Proteolytically cleavable chimeric polypeptides and methods of use thereof - Google Patents

Proteolytically cleavable chimeric polypeptides and methods of use thereof

Info

Publication number
SG11201901528RA
SG11201901528RA SG11201901528RA SG11201901528RA SG11201901528RA SG 11201901528R A SG11201901528R A SG 11201901528RA SG 11201901528R A SG11201901528R A SG 11201901528RA SG 11201901528R A SG11201901528R A SG 11201901528RA SG 11201901528R A SG11201901528R A SG 11201901528RA
Authority
SG
Singapore
Prior art keywords
california
methods
international
chimeric polypeptides
street
Prior art date
Application number
SG11201901528RA
Inventor
Wendell A Lim
Kole T Roybal
Jasper Z Williams
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11201901528RA publication Critical patent/SG11201901528RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) W I PO I PCT olimion °nolo III 111111111o1110 Ho Imo oimIE (10) International Publication Number WO 2018/039247 Al (51) International Patent Classification: C07K 16/30 (2006.01) C07K 19/00 (2006.01) (21) International Application Number: PCT/US2017/048040 (22) International Filing Date: 22 August 2017 (22.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/378,614 23 August 2016 (23.08.2016) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US). (72) Inventors: LIM, Wendell A.; 149 Collins Street, San Fran- cisco, California 94118 (US). ROYBAL, Kole T.; 600 16th Street, San Francisco, California 94158 (US). WILLIAMS, Jasper Z.; 600 16th Street, San Francisco, California 94158 (US). (74) Agent: GUEDELHOEFER, Otto C.; 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 N 71- (54) Title: PROTEOLYTICALLY CLEAVABLE CHIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF cn (57) : The instant disclosure provides chimeric polypeptides which modulate various cellular processes following a cleavage f .r1 event induced upon binding of a specific binding member of the polypeptide with its binding partner. Methods of using chimeric polypeptides to modulate cellular functions, including e.g., induction of gene expression, are also provided. Nucleic acids encoding the subject chimeric polypeptides and associated expression cassettes and vectors as well as cells that contain such nucleic acids and/or 1-1 © expression cassettes and vectors are provided. Also provided, are methods of treating a subject using the described components and f'1 methods as well as kits for practicing the subject methods.
SG11201901528RA 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof SG11201901528RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662378614P 2016-08-23 2016-08-23
PCT/US2017/048040 WO2018039247A1 (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201901528RA true SG11201901528RA (en) 2019-03-28

Family

ID=61245300

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901528RA SG11201901528RA (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG10201913583QA SG10201913583QA (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913583QA SG10201913583QA (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof

Country Status (9)

Country Link
US (2) US11401332B2 (en)
EP (1) EP3504245A4 (en)
JP (2) JP2019528077A (en)
KR (2) KR102637610B1 (en)
CN (1) CN109843929A (en)
AU (1) AU2017316649A1 (en)
CA (1) CA3034093A1 (en)
SG (2) SG11201901528RA (en)
WO (1) WO2018039247A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
AU2016219785B2 (en) 2015-02-20 2021-10-28 Ohio State Innovation Foundation Bivalent antibody directed against NKG2D and tumor associated antigens
US11045543B2 (en) 2015-04-06 2021-06-29 Cytoimmune Therapeutics, Inc. EGFR-directed car therapy for glioblastoma
CN110225760B (en) * 2016-09-15 2023-11-07 埃里西拉医疗公司 T cell immunotherapy
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
WO2019178576A1 (en) * 2018-03-16 2019-09-19 Cytoimmune Therapeutics, LLC Bispecific antibody car cell immunotherapy
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
JP2021520352A (en) 2018-04-04 2021-08-19 アリヴィオ セラピューティクス， インコーポレイテッド Self-assembled gel for controlled delivery of biopharmaceuticals and method for producing the same
EP3773623A4 (en) * 2018-04-06 2022-01-05 The Regents of The University of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
EP3847650A1 (en) 2018-09-06 2021-07-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
WO2020118076A1 (en) * 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
EP3906047A4 (en) * 2019-01-03 2022-10-05 Nanjing Legend Biotech Co., Ltd. Modified immune cells expressing flagellin polypeptide
MX2022001711A (en) * 2019-08-09 2022-05-10 A2 Biotherapeutics Inc Cell-surface receptors responsive to loss of heterozygosity.
WO2021061859A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Novel receptors for ligand-dependent transcriptional regulation
WO2021061791A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
EP4034252A4 (en) * 2019-09-24 2023-11-08 The Regents of the University of California Notch receptors with hinge domain
EP4034254A4 (en) * 2019-09-24 2023-11-01 The Regents of the University of California Receptors with heterologous transmembrane domain
CN110716044B (en) * 2019-10-23 2023-04-18 郑州大学 Serum protein marker, kit and detection method for early screening and diagnosis of esophageal squamous carcinoma
CN110970090B (en) * 2019-11-18 2021-06-29 华中科技大学 Method for judging similarity between polypeptide to be processed and positive data set peptide fragment
JPWO2021131944A1 (en) * 2019-12-27 2021-07-01
EP4168562A2 (en) * 2020-06-18 2023-04-26 Flagship Pioneering Innovations VI, LLC Methods and compositions for modulating cells and cellular membranes
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating ceacam positive cancers
MX2023002041A (en) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Compositions and methods for treating mesothelin positive cancers.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (en) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 Chimeric antigen receptor system with adaptable receptor specificity
WO2022183056A1 (en) * 2021-02-26 2022-09-01 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
CN117255799A (en) * 2021-03-23 2023-12-19 加利福尼亚大学董事会 Synthetic membrane-to-membrane proteolytic receptors for custom antigen-induced transcriptional regulation
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
CN114736308B (en) * 2022-03-15 2022-12-27 四川宜美康科技有限公司 Preparation and application of coccidian antigen peptide/IL 5 fusion protein gene engineering bacteria

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
GB0220658D0 (en) 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
WO2009040782A2 (en) 2007-09-28 2009-04-02 Royal College Of Surgeons In Ireland A method of assessing colorectal cancer status in an individual
SG192467A1 (en) 2008-07-08 2013-08-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
EP2558571A4 (en) 2010-04-16 2014-09-24 Immune Disease Inst Inc Sustained polypeptide expression from synthetic, modified rnas and uses thereof
ES2743738T3 (en) 2012-10-02 2020-02-20 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015066551A2 (en) 2013-10-31 2015-05-07 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
US9730935B2 (en) 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
SG11201605585SA (en) 2014-01-08 2016-08-30 Univ Leland Stanford Junior Targeted therapy for small cell lung cancer
ES2764471T3 (en) 2014-02-14 2020-06-03 Univ Texas Chimeric antigen receptors and manufacturing procedures
CA2939711C (en) 2014-02-21 2020-09-29 Cellectis Method for in situ inhibition of regulatory t cells
EP3174546B1 (en) * 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
RU2764074C2 (en) 2014-08-28 2022-01-13 Байоатла, Ллк Conditionally active chimeric antigen receptors for modified t-cells
CA2959428A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
US10765729B2 (en) 2014-12-09 2020-09-08 Sapporo Medical University Tumor antigen peptide
AU2016222887B2 (en) 2015-02-24 2022-07-14 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof

Also Published As

Publication number Publication date
WO2018039247A1 (en) 2018-03-01
KR20230038295A (en) 2023-03-17
KR102637610B1 (en) 2024-02-19
JP2019528077A (en) 2019-10-10
EP3504245A1 (en) 2019-07-03
CA3034093A1 (en) 2018-03-01
CN109843929A (en) 2019-06-04
US11401332B2 (en) 2022-08-02
EP3504245A4 (en) 2020-04-22
US20220324982A1 (en) 2022-10-13
US20190202918A1 (en) 2019-07-04
KR20190051956A (en) 2019-05-15
JP2022106714A (en) 2022-07-20
SG10201913583QA (en) 2020-02-27
AU2017316649A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
SG11201901528RA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201908391XA (en) Methods for modulating an immune response
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201908396PA (en) Methods of treating tumor
SG11201901131VA (en) Substituted pyrrolizine compounds and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201806398YA (en) Optimized factor viii genes
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201907653QA (en) Compositions and methods for enhanced gene expression
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201906341XA (en) Improved serum albumin binders
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201407802WA (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof